SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (15839)2/22/2005 1:28:18 PM
From: Sam Citron  Respond to of 52153
 
Roth conference at 12N today EST [LGND] corporate-ir.net



To: Arthur Radley who wrote (15839)2/22/2005 3:25:51 PM
From: Biomaven  Read Replies (2) | Respond to of 52153
 
<LGND>

I really don't know if there's any good way to handicap this Targretin trial. But the one thing to emphasize is that the drug is already on the market, and so a good result will produce sales quickly. And a bad result won't kill the company - it would be just one more in a line of disappointments.

The IV's on the April options are pretty high, so no huge bargains to be had.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News